Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 May;27(3):171-4.
doi: 10.1177/1533317512442999.

Which cholinesterase inhibitor is the safest for the heart in elderly patients with Alzheimer's disease?

Ahmet Turan Isik  1 , Ergun Bozoglu, Adnan Yay, Pinar Soysal, Umit Ateskan
Affiliations

Which cholinesterase inhibitor is the safest for the heart in elderly patients with Alzheimer's disease?

Ahmet Turan Isik et al. Am J Alzheimers Dis Other Demen. 2012 May.

Abstract

Objective: Cholinesterase inhibitors (ChEIs) are widely used for the treatment of Alzheimer's disease (AD); however, their cholinergic side effects on the cardiovascular system are still unclear. In this study, we aimed to examine the side effects caused by donepezil, rivastigmine, and galantamine on cardiac rhythm and postural blood pressure changes in elderly patients with AD.

Methods: Of 204 consecutive elderly patients who were newly diagnosed with AD, 162 were enrolled and underwent comprehensive geriatric assessments. The electrocardiographs (ECGs) and blood pressures were recorded at the baseline and 4 weeks after the dose of 10 mg/d of donepezil, 10 cm(2)/d of rivastigmine, and 24 mg/d of galantamine.

Results: There were no changes relative to the baseline in any of the ECG parameters or arterial blood pressure with any of the administered ChEIs.

Conclusion: It was demonstrated that none of the 3 ChEIs were associated with increased negative chronotropic, arrhythmogenic, and hypotensive effects for the elderly patients with AD.

PubMed Disclaimer

Conflict of interest statement

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Figures

Figure 1.
Figure 1.
Mean changes in ECG parameters from baseline in the each treatment group. The mean changes in ECG parameters from baseline for each treatment group were not significant (P >.05 for each comparison). PR indicates PR interval; QRS, QRS duration; QT, QT interval; QTc, corrected QT interval.
See this image and copyright information in PMC

References

    1. Shintani EY, Uchida KM. Donepezil: an anticholinesterase inhibitor for Alzheimer’s disease. Am J Health Syst Pharm. 1997;54(24):2805–2810. - PubMed
    1. Masuda Y. Cardiac effect of cholinesterase inhibitors used in Alzheimer’s disease-from basic research to bedside. Curr Alzheimer Res. 2004;1(4):315–321. - PubMed
    1. Malone DM, Lindesay J. Cholinesterase inhibitors and cardiovascular disease: a survey of old age psychiatrists’ practice. Age Ageing. 2007;36(3):331–333. - PubMed
    1. Keren A, Tzivoni D, Gavish D, Levi J, Gottlieb S, Benhorin J, et al. Etiology, warning signs and therapy of torsade de pointes. A study of 10 patients. Circulation. 1981;64(6):1167–1174. - PubMed
    1. Williams BR, Nazarians A, Gill MA. A review of rivastigmine: a reversible study cholinesterase inhibitor. Clin Ther. 2003;25(6):1631–1653. - PubMed

MeSH terms